Contact Us
Drug Search Results
More Filters [+]

Rosiglitazone

Alternative Names: rosiglitazone, avandia, avandamet, rosiglitazonmaleat, avaglim, avandaryl
Latest Update: 2024-06-17
Latest Update Note: News Article

Product Description

Rosiglitazone, a thiazolidinedione antidiabetic agent, improves insulin resistance, a key underlying metabolic abnormality in most patients with type 2 (non-insulin-dependent) diabetes mellitus. In animal models of insulin resistance, rosiglitazone decreased plasma glucose, insulin and triglyceride levels and also attenuated or prevented diabetic nephropathy and pancreatic islet cell degeneration (Sourced from: https://pubmed.ncbi.nlm.nih.gov/10400405/)

Mechanisms of Action: PPAR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Bangladesh | Brazil | Canada | Chile | Colombia | Croatia | Denmark | Dominican Republic | Egypt | European Medicines Agency | Germany | Hungary | India | Ireland | Italy | Lithuania | Morocco | New Zealand | Pakistan | Peru | Portugal | Russia | Slovenia | Spain | Sweden | Taiwan | Thailand | United Kingdom | Venezuela | Vietnam

Approved Indications: General Diabetes | Type 2 Diabetes | General Diabetes | Type 2 Diabetes

Known Adverse Events: Headache | Diarrhea | Dyspepsia | Nasopharyngitis | Pharyngitis | Hypoglycemia

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rosiglitazone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

06/17/2024

News Article

 MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

11/02/2023

News Article

 Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023

06/07/2023

News Article

 Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023

06/07/2023

News Article

 Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions